Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondria-Targeting Moieties Based on N-Tethered Pyridinium Cations.

Angewandte Chemie (International ed. in English)·2026
Same author

Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer.

iScience·2026
Same author

pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma.

Acta physiologica (Oxford, England)·2026
Same author

Correction: Preserved fascicular architecture predicts neuroma pain: a morphometric study.

Acta neuropathologica communications·2026
Same author

Hyperspectral Imaging Reveals High Water and Hemoglobin Content at Rest and Decreased Oxygen Levels After Physical Activity at the Residual Limb of Non-Dysvascular Lower Limb Amputees.

Microcirculation (New York, N.Y. : 1994)·2026
Same author

New mitochondrial K<sub>V</sub>1.3 conjugates are potent and specific inducers of apoptosis in cancer models.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

The biological role of CCR4 and its ligands CCL17 and CCL22 in atopic dermatitis: therapeutic implications and future directions.

Expert opinion on therapeutic targets·2026
Same journal

Hepatocyte nuclear factor 4α - prospects for therapeutic targeting.

Expert opinion on therapeutic targets·2026
Same journal

The role of bile acid receptors in cholestatic liver disease: pathophysiological insights and therapeutic advances.

Expert opinion on therapeutic targets·2026
Same journal

Molecular insights for targeting the Nrf1 pathway in hepatocellular carcinoma.

Expert opinion on therapeutic targets·2026
Same journal

Transient receptor potential (TRP) channels: an emerging therapeutic target for the treatment of cardiac hypertrophy.

Expert opinion on therapeutic targets·2026
Same journal

The AT<sub>2</sub> receptor as a potential target for autosomal dominant polycystic kidney disease therapy?

Expert opinion on therapeutic targets·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Eag1 as a cancer target.

Luis A Pardo1, Walter Sühmer

  • 1Max Planck Institute of Experimental Medicine, Department of Molecular Biology of Neuronal Signals, Hermann-Rein-Str 3, 37075 Göttingen, Germany. pardo@em.mpg.de

Expert Opinion on Therapeutic Targets
|June 17, 2008
PubMed
Summary
This summary is machine-generated.

Ether à go-go 1 (Eag1) channels are promising cancer targets. Their restricted expression and unique properties make Eag1 valuable as a tumor marker and for targeted cancer therapies.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Experiment Videos

Last Updated: Jul 4, 2026

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Area of Science:

  • Oncology
  • Molecular Biology
  • Biophysics

Background:

  • Ion channels are increasingly recognized as potential cancer targets.
  • Various ion channels show promise for cancer management strategies.

Purpose of the Study:

  • To investigate the ether à go-go 1 (Eag1) channel as a potential cancer target.
  • To highlight Eag1's unique expression and electrophysiological characteristics.

Main Methods:

  • Literature review on Eag1 ion channels.
  • Analysis of Eag1's role in cancer in relation to other ion channels.

Main Results:

  • Eag1 exhibits a restricted expression pattern.
  • Eag1 possesses distinctive electrophysiological properties relevant to cancer.

Conclusions:

  • Eag1 is a promising candidate for cancer therapy and diagnostics.
  • Its restricted expression makes Eag1 a potential tumor marker for therapeutic decisions.
  • Eag1 can serve as a target for therapeutic agents.